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Bothrops asper represents the clinically most important snake species in Central America
and Northern South America, where it is responsible for an estimated 50–80% of snake-
bites. Compositional variability among the venom proteomes of B. asper lineages across its
wide range mirrors clinical differences in their envenomings. Bothropic antivenoms gener-
ated in a number of Latin American countries commonly exhibit a certain degree of paraspe-
cific effectiveness in the neutralization of congeneric venoms. Defining the phylogeographic
boundaries of an antivenom’s effectivity has implications for optimizing its clinical use. How-
ever, the molecular bases and impact of venom compositions on the immune recognition
and neutralization of the toxic activities of across geographically disparate populations of B.
asper lineages has not been comprehensively studied.
Methodology/Principal findings
Third-generation antivenomics was applied to quantify the cross-immunorecognizing capac-
ity against the individual components of venoms of three B. asper lineages (B. asper (sensu
stricto), B. ayerbei and B. rhombeatus) distributed in south-western (SW) Colombia, of six
Latin American antivenoms, produced against homologous (Colombia, INS-COL and PRO-
BIOL) and Costa Rica (ICP)), and heterologous (Argentina (BIOL), Perú (INS-PERU) and
Venezuela (UCV)) bothropic venoms. In vivo neutralization assays of the lethal, hemor-
rhagic, coagulant, defibrinogenating, myotoxic, edematogenic, indirect hemolytic, and pro-
teolytic activities of the three SW Colombian B. asper lineage venoms were carried to
compare the preclinical efficacy of three (Colombian INS-COL and PROBIOL, and Costa
Rican ICP) antivenoms frequently used in Colombia. Antivenomics showed that all the six
antivenom affinity matrices efficiently immunoretained most of the B. asper lineages venom
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proteins and exhibited impaired binding towards the venoms’ peptidomes. The neutraliza-
tion profile of the INS-COL, PROBIOL and ICP antivenoms towards the biological activities
of the venoms of SW Colombian B. asper (sensu stricto), B. ayerbei and B. rhombeatus line-
ages was coherent with the antivenomics outcome. In addition, the combination of in vitro
(antivenomics) and in vivo neutralization results allowed us to determine their toxin-specific
and venom neutralizing antibody content. Noteworthy, heterologous INS-PERU, BIOL, and
UCV bothropic antivenoms had equal or higher binding capacity towards the venoms com-
ponents of SW Colombian B. asper lineages that the homologous Colombian and Costa
Rican antivenoms.
Conclusions/Significance
The combined in vitro and in vivo preclinical outcome showed that antivenoms manufac-
tured in Colombia and Costa Rica effectively neutralize the major toxic activities of SW
Colombian B. asper lineage venoms. The antivenomics profiles of the heterologous antiven-
oms manufactured in Argentina, Venezuela, and Perú strongly suggests their (pre)clinical
adequacy for the treatment of B. asper lineage envenomings in SW Colombia. However,
their recommendation in the clinical setting is pending on in vivo neutralization testing and
clinical testing in humans. Bothrops asper is a highly adaptable snake species complex,
which is considered the most dangerous snake throughout much of its distribution range
from the Atlantic lowland of eastern México to northwestern Perú. Antivenoms are the only
scientifically validated treatment of snakebite envenomings. Venom variation is particularly
common in wide ranging species, such as B. asper, and may result in variable clinical pre-
sentations of envenomings, as is the case for the B. asper species complex, potentially
undermining the efficacy of snakebite treatments depending on the immunization mixture
used in the generation of the antivenom. Conversely, phylogenetic conservation of antigenic
determinants confers an unpredictable degree of paraspecificity to homologous antivenoms
produced for a geographic area, but also to heterologous congeneric antivenoms, towards
the venom components of allopatric conspecific populations. This work aimed at comparing
the preclinical profile of a panel of Latin American homologous and heterologous antiven-
oms against the venoms of B. asper lineages distributed in SW Colombia. The outcome of
this study strongly suggests the suitability of considering the heterologous antivenoms BIOL
(Argentina), UCV (Venezuela) and INS-PERU (Perú) as alternatives to homologous Colom-
bian INS-COL and PROBIOL and Costa Rican ICP antivenoms for the treatment of enve-
nomings by B. asper (sensu stricto) in W Colombia and Ecuador, B. ayerbei in Cauca and
Nariño (Colombia), and B. rhombeatus in Cauca river valley, SW Colombia.
Author summary
Snakebite envenoming is an important occupational health problem, particularly in rural
areas of developing countries. The timely administration of an effective antivenom
remains the mainstay of snakebite management. However, the use of antivenoms is often
limited by non-availability due to high cost or by lack of effectiveness. Antivenom short-
age can be addressed through the generation of novel polyspecific antivenoms of wide
clinical efficacy against the venoms of the medically-relevant snake species within the
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geographical range where these antivenoms are intended to be deployed, but also by opti-
mizing the paraspecific use of current antivenoms. In Colombia, antivenoms are supplied
by two manufacturers, one public, the Instituto Nacional de Salud (INS), and one private,
Laboratorios Probiol (PROBIOL). However, the antivenom supply in Colombia has tradi-
tionally been insufficient, a circumstance that has led the Colombian Ministerio de Salud
y Protección Social to issue several resolutions and decrees to announce this health emer-
gency in the country, and to import antivenoms produced in México and Costa Rica.
Contrary to these countries, where B. asper represents the only species of the genus, in SW
Colombia three close phylogenetically related B. asper lineages, B. asper (sensu stricto), B.
rhombeatus, and B. ayerbei, are responsible for most severe cases of snakebite accidents
and exhibit remarkable differences in the physiopathological profile of their envenomings.
This work aimed to assess the immunorecognition characteristics of a panel of antiven-
oms manufactured in Colombia, Costa Rica, Argentina, Perú and Venezuela towards the
venoms of the three SW Colombian B. asper lineages. Additionally, combined quantitative
in vitro and in vivo data show that the homologous antivenoms produced in Colombia
(INS-COL, PROBIOL) and Costa Rica (ICP) effectively neutralize the lethality and the
major toxic activities tested of the three SW Colombian B. asper lineage venoms. Heterol-
ogous Argentinian (BIOL), Venezuelan (UCV) and Peruvian (INS-PERU) antivenoms
also showed comparable, even higher, effective immunocapturing ability towards the
venom proteomes of SW Colombian B. asper (sensu stricto), B. rhombeatus, and B. ayerbei,
than the Colombian and Costa Rican antivenoms. These results are in line with previous
studies highlighting the notable conservation of paraspecific antigenic determinants
across the phylogeny of genus Bothrops, and advocate for considering the heterologous
Argentinian, Venezuelan and Peruvian antivenoms as further therapeutic alternatives for
the treatment of B. asper spp. snakebites in Colombia.
Introduction
Snakebite envenoming is an occupational hazard and a WHO category A neglected tropical
disease (NTD) [1] that annually kills 81,000–138,000 people living in economically depressed
rural communities of Africa, Asia and Latin America, where the provision of health services is
limited or inexistent [2,3]. Snakebite leaves victims with permanent physical sequelae and
chronic mental morbidity that affects not only the surviving victims, often young agricultural
workers but also their entire families, which enter a cycle of generational poverty that is diffi-
cult to break [4–6].
In Latin America and the Caribbean 137,000–150,000 snakebite envenomings occur each
year, resulting in 3,400–5,000 deaths [2]. With 40,820–44,230 snakebite accidents a year and a
mortality rate of 0.05–0.5% [7], the South American subcontinent stands as the most affected
region of the New World. Bothropic envenoming is caused by snake species of genera
Bothrops, Bothriechis, Bothrocophias and Porthidium. Among them, Bothrops species have the
highest epidemiological importance. Particularly B. asper, a species complex widely distributed
from México to Perú, where it is commonly known as nauyaca, barba amarilla, terciopelo,
equis/talla equis, equis patiana, cacica, pelo de gato, boquidorá, mapaná, damá, tapa, etc.
(http://snakedatabase.org/species/Bothrops/asper) [8–10], is responsible for 50–80% of the
snakebites and 60–90% of fatalities over much of its range [10,11]. It inhabits the tropical rain-
forest and tropical evergreen forest more frequently, but due to its ease of adapting to different
environments it is also found close to crops or human dwellings [12]. B. asper has crepuscular
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and nocturnal habits and is recognized as an extremely dangerous snake by its reputation as
an irritable snake of large size, rapid reactions and unpredictable behavior, and the high quan-
tity of highly lethal venom (LD50 between 2.06 (1.89–2.04) μg newborns’ venom/g mouse body
weight and 3.82 (3.65–4.00) μg adults’ venom/g mouse; doses reported for snakes from Pacific
Costa Rican population) that can deliver in a bite [12,13]. Envenomings by B. asper are charac-
terized by local effects such as edema detectable in the first minutes after the bite; local hemor-
rhage evident as bleeding or ecchymosis; blisters, regional lymphadenitis, paresthesia,
hypothermia, compartment syndrome, dermonecrosis, myonecrosis, abscesses, and gangrene
[10,11]. Frequent systemic effects include defibrinogenation, thrombocytopenia, hypotension,
massive pulmonary and/or mesenteric capillary micro thrombosis, and these clinical manifes-
tations may become life-threatening as the result of shock and multi-organ failure [10,11].
In Colombia, along the period 2008–2019, the annual cases of snakebites reported by the
National Public Health Surveillance System (SIVIGILA) of the National Health Institute (INS)
were 3,129 to 5,603 (7–11.1 cases/100,000 population per year) [14–17]. The majority of snake-
bite envenomings (90–95%) are inflicted by pitvipers of the Viperidae family and involve spe-
cies from the genera Bothrops (Bothrops asper, B. atrox, B. bilineatus, B. pulcher, B. punctatus,
B. taeniatus), Bothriechis (B. schlegelii), Bothrocophias (B. campbelli, B. colombianus, B. hyo-
prora, B. microphthalmus, B. myersi) and Porthidium (P. lansbergii, P. nasutum), most notably
(50–80%) by B. asper in lowlands and inter-Andean valleys. Two percent of snakebites is due
to the bushmaster Lachesis spp. (L. acrochorda and L. muta) in tropical rain forest; and 1% of
envenomings are due to bites by the rattlesnake Crotalus durissus cumanensis, a species inhab-
iting desertic dry or semidry lowlands in the Caribbean region, in the high valley of the Mag-
dalena River, in the Orinochian region, and savannahs (Yarı́ River) of the Caquetá
Department. Ophidian accidents caused by coral snakes (e.g., M. ancoralis, M. clarki, M. disso-
leucus, M. dumerilii, M. mipartitus, M. nigrocinctus, M. lemniscatus, Micrurus surinamensis)
account for about 1% of the total snakebite envenomings in Colombia. The remaining 1–5%
are inflicted by other aglyphous and opisthoglyphous snake species, mainly from the Colubri-
dae family [10,18]. The estimated fatality rate is 1–3% [11,18], although with a pattern of noto-
rious regional variation, and 6–10% of patients suffer some type of life-long sequelae, mainly
as a result of dermonecrosis and myonecrosis. Due to their low population density and abun-
dant ophidian fauna, the highest snakebite incidence occurs in the Orinochian and Amazo-
nian regions (Fig 1) [15–17,19], where B. atrox inflicts 90% of the snakebites [20]
The SW Colombian Departments of Nariño and Cauca are characterized by their impres-
sive mountainous relief belonging to the northern portion of the great Andean mountain sys-
tem, which extends along the Pacific coast of South America. Its orogeny makes the
Colombian Andean natural region one of the most biodiverse in the country, including ven-
omous snakes of the Viperidae and Elapidae families (Fig 1) [21,22]. Saldarriaga-Córdoba
et al. [23] and Salazar-Valenzuela et al. [24] have recently described the existence of phylogeo-
graphic structure across B. asper distribution. Three B. asper lineages found in Nariño and
Cauca Departments (Colombia), B. asper (sensu stricto) on the Pacific versant of the western
mountain range, B. ayerbei in the upper Patia river valley and B. rhombeatus in the Cauca river
valley [25], account for the largest proportion of snakebites in SW Colombia [22]. Two hun-
dred and thirty-nine snakebite cases occurred in Nariño and Cauca in 2019, 56 cases more
than 2018. Fig 1 lists the species that potentially cause these accidents in the Departments of
Nariño and Cauca. Although this figure is lower than those documented in other Departments
(e.g. Antioquia and Norte de Santander) [14–17], the marginal areas where accidents occur
along with the limited distribution of antivenoms, among others factors, prevent victims from
accessing proper treatment and, as a consequence, there is high underreporting of cases, deaths
increase, and physical, psychological, social and economic sequelae are serious [3,21].
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The Instituto Nacional de Salud (INS) and Laboratorios Probiol (PROBIOL) manufacture
and commercialize in Colombia antivenoms generated from plasma of hyperimmunized
horses with mixtures of venoms from B. asper (sensu lato), B. atrox and Crotalus durissus
cumanensis, and Laboratorios Probiol additionally includes venom of Lachesis muta in the
immunization mixture [26]. However, antivenom supply in the country has traditionally been
insufficient and the Colombian Ministerio de Salud y Protección Social has issued several reso-
lutions and decrees declaring health emergencies owing to the scarcity of antivenoms, having
been necessary to import them from other countries, particularly México and Costa Rica
[11,27]. An analysis of the availability of antivenom in the period 1992 to 2016 revealed that
compared to the need for +30,000 vials per year, the average national production in that period
was 22,000 vials; production exceeded the demand only in some years [27]. Despite antivenom
shortage is clearly related to an increase in the mortality rate, and the impact of snakebites
could be reduced by the Government demonstrating more interest in this public health issue,
initiatives such as the creation of additional antivenom-producing companies have not been
materialized [26,27]. In addition, to complicate the picture, clinical observations over two
decades have evidenced distinctive local and systemic signs and symptoms of envenoming
caused by different B. asper lineages [28–31], with B. asper (sensu stricto) venom causing
Fig 1. Snakebite incidence in Colombia. The figure is adapted from the event report, epidemiological period XIII,
Colombia, 2019 [17]. White dashed lines delimit the Colombian Insular (1), Caribbean (2), Andean (3), Pacific (4),
Orinochian (5) and Amazonian (6) natural regions. Snakebite incidence data from the Insular region (San Andrés,
Providencia, and Santa Catalina) were "missing or excluded" in the 2019 SIVIGILA-INS event report. The left panel
highlights species within the clinically important snake families Viperidae and Elapidae with distribution in the
Departments of Nariño and/or Cauca, which can potentially cause snakebite accidents in this region. The list was
compiled from Ayerbe and Latorre [22] and Sevilla-Sánchez et al. [21]. 1B. asper includes the lineages B. asper (sensu
stricto), B. rhombeatus and B. ayerbei. The map was prepared in the QGIS software, version 3.14.15-Pi, using public
domain maps available in QGIS OpenLayers Plugin, and the Geoportals of the Instituto Geográfico Agustı́n Codazzi-
IGAC (https://geoportal.igac.gov.co/contenido/datos-abiertos-cartografia-y-geografia) and the Departamento
Administrativo Nacional de Estadı́stica-DANE (https://geoportal.dane.gov.co/servicios/descarga-y-metadatos/
descarga-mgn-marco-geoestadistico-nacional/) from Colombia. All maps were used under a CC-BY 4.0 license.
https://doi.org/10.1371/journal.pntd.0009073.g001
PLOS NEGLECTED TROPICAL DISEASES Testing Latin American antivenoms against SW Colombian B. asper lineage venoms
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0009073 February 1, 2021 5 / 36
stronger myotoxic activity than those of B. ayerbei and B. rhombeatus, with the latter venom
being the most coagulant, whereas B. ayerbei venom is poorly myotoxic but the most hemorrhagic
among the three lineage venoms [28,29]. In line with these functional data, comparative venomics
of B. asper lineages distributed from México to Ecuador, including venoms from México, Costa
Rica, and populations from the Pacific side of Ecuador and SW Colombia, revealed similar overall
toxin family compositions albeit exhibiting quantitative differences chiefly in the relative abun-
dance of their four major protein families, snake venom metalloproteinase (SVMP), serine pro-
teinase (SVSP), phospholipase A2 (PLA2) and C-type lectin-like (CTL) [32].
The cross-reactivity of mono- and polyvalent antivenoms manufactured in México (Birmex,
Bioclon), Costa Rica (ICP), Venezuela (UCV), and Colombia (INS-COL, PROBIOL) towards B.
asper venoms from México [33], Guatemala [34], Costa Rica [35,36], Panamá [37], northern
Colombia [38], and Ecuador [39] have been reported. The aim of this work was to perform a
detailed comparative preclinical analysis of a panel of six antivenoms manufactured in Colom-
bia, Venezuela, Costa Rica, Perú and Argentina to quantify their capability to immunorecognize
the toxins of B. asper lineage venoms (B. asper (sensu stricto), B. rhombeatus, and B. ayerbei)
from Department of Cauca (Colombia). The neutralization of the lethal and major toxic activi-
ties of these B. asper lineage venoms by the polyvalent Colombian (INS-COL, PROBIOL) and
Costa Rican (ICP) antivenoms was also assessed through combined in vivo and in vitro assays.
Materials and methods
Ethics statement
Assays performed in mice were approved by the Institutional Committee for the Care and Use
of Laboratory Animals (CICUA) of the University of Costa Rica (approval number 082–08).
Snake venoms
Venoms of adult snakes from Department of Cauca (Colombia), two of B. asper from the
municipalities of Playa Rica and Huisitó (El Tambo in the Pacific coast), four of B. ayerbei
from the Alto Patı́a river valley (El Tambo, San Joaquı́n, Pomorroso, Cauca) and four of B.
rhombeatus from Cauca river valley (Popayán and Cajibı́o municipalities), were obtained from
wild-caught specimens maintained in the serpentarium of the Centro de Investigaciones Bio-
médicas de la Universidad del Cauca-Bioterio (CIBUC-Bioterio). Venoms were collected by
allowing the snake to bite on a glass conical funnel covered with Parafilm. Crude venom was
lyophilized and stored at -20˚C until used. Equal quantities of each lineage venom were pooled
to perform the in vitro and in vivo assays.
Antivenoms
Six commercial polyvalent antivenoms (Table 1) were tested: INS-COL from the Instituto
Nacional de Salud of Colombia, batch numbers 15SAP01 and 16SAP01 with expiry dates 12/
2018 and 04/2019, respectively; PROBIOL produced by Laboratorios Probiol S.A. (Colombia),
batch number AP066XI16-ES with expiry date 11/2018; ICP-polyvalent from Instituto Clodo-
miro Picado (Costa Rica), batch 6060618 POLF with expiry date 12/2023; INS-PERU from
Instituto Nacional de Salud of Perú, batch 10200045 with expiry date 02/2018; UCV, produced
by Centro de Biotecnologı́a de la Unidad de Farmacia of the Universidad Central de Venezu-
ela, batch 179 with expiry date 07/2017; and BIOL produced by Instituto Biológico Argentino
S.A.I.C., batch 3664 with expiry date 10/2018.
All antivenoms were generated from plasma of horses hyperimmunized against different
mixtures of venoms: B. atrox (Meta and Casanare, Orinoquı́a; Amazonas and Caquetá,
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Amazonı́a), B. asper (sensu stricto, Departments of Atlántico, Bolı́var, Cauca (Isla Gorgona),
Cauca river valley (Pacific region), and Tolima); B. rhombeatus, Antioquia), and Crotalus. d.
cumanensis (INS-COL); B. atrox (Meta and Casanare, Orinoquia; Amazonas and Caquetá,
Amazonı́a), B. asper (sensu stricto, Costa Atlántica; B. rhombeatus, Magdalena Medio river val-
ley and Cauca river valley), Crotalus. d. cumanensis, and Lachesis muta (PROBIOL); B. asper,
C. simus, Crotalus vegrandis and L. stenophrys (ICP); B. atrox, B. barnetti, B. brazili, B. pictus,
and Bothrocophias hyoprora (INS-PERU); B. atrox, B. colombiensis, B. venezuelensis, Porthi-
dium lansbergii hutmanni; C.d. cumanensis, and C.d. ruruima (UCV); and B. asper, C. simus,
and L. muta (BIOL). INS-COL, PROBIOL, ICP, INS-PERU antivenoms are composed of
whole immunoglobulins (IgGs), whereas the UCV and BIOL antivenoms are made up of the
antigen-binding fragments F(ab’)2 purified from pepsin-digested whole hyperimmune serum.
Characterization of the antivenoms
Physicochemical characteristics of the antivenoms, such as color, odor, and pH were examined
and recorded. The antivenom total protein concentration (mg/mL) was determined spectro-
photometrically using an extinction coefficient for a 1 mg/mL concentration (ε0.1%) at 280 nm
of 1.36 (mg/mL)−1 cm−1 [40,41]. The homogeneity and purity of the antivenoms were assessed
by non-reducing SDS-PAGE analysis in 8.5% polyacrylamide gels and proteomics characteri-
zation of the Coomassie Brilliant Blue G-250-stained protein bands [42]. To this end, protein
bands of interest were excised, subjected to in-gel reduction (10 mM dithiothreitol, 30 min at
65˚C) and alkylation (50 mM iodacetamide, 2 h in the dark at room temperature), followed by
overnight digestion with sequencing-grade trypsin (66 ng/μL in 25 mM ammonium bicarbon-
ate, 10% ACN; 0.25 μg/sample) using an automated Genomics Solution ProGest Protein
Digestion Workstation. Tryptic digests were dried in a vacuum centrifuge (SPD SpeedVac,
ThermoSavant), redissolved in 15 μL of 5% ACN containing 0.1% formic acid, and submitted
to LC-MS/MS. Tryptic peptides were separated by nano-Acquity UltraPerformance LC
(UPLC) using BEH130 C18 (100μm × 100 mm, 1.7μm particle size) column in-line with a
Waters SYNAPT G2 High Definition Mass Spectrometry System. The flow rate was set to







Neutralizing potency per vial (mg
venom/10 mL antivenom)a
Instituto Nacional de Salud, Colombia
(INS-COL)
IgG Liquid None Weak 6 56.8 ± 3.2b Bothrops sp (70 mg), Crotalus sp (10 mg).




Strong 7 200.7b Bothrops asper (25 mg), B. atrox (25 mg),
Lachesis muta (10 mg), Crotalus durissus
(5 mg).
Instituto Clodomiro Picado, Costa Rica
(ICP)
IgG Lyophilized Light Blue Strong 6 59.7 ± 0.1b Bothrops asper (30 mg), Crotalus simus,
Crotalus vegrandis (20 mg), Lachesis
stenophrys (30 mg).
Instituto Nacional de Salud, Perú
(INS-PERU)
IgG Liquid None Weak 6 59.1 ± 0.1b Bothrops atrox, B. brazili, B. pictus, B.
barnetti, Bothrocophias hyoprora (25 mg).
Centro de Biotecnologı́a de la Unidad de
Farmacia de la Universidad Central de
Venezuela (UCV)
F(ab’)2 Liquid None N.D N.D 41.9
c Bothrops colombiensis (20 mg), Crotalus
durissuss cumanensis (15 mg).
Instituto Biológico Argentino S.A.I.C
(BIOL)
F(ab’)2 Lyophilized White N.D N.D 59.3
b Bothrops alternatus (12.5 mg), B. diporus
(12.5 mg), Crotalus durissus (4 mg).
a Information obtained from the inserts of the products.
b Protein concentration was estimated by Lambert-Beer Law.
c Data provided by the manufacturer (Mariana del Valle Cepeda Briceño, personal communication). N.D: not determined.
https://doi.org/10.1371/journal.pntd.0009073.t001
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0.6 μL/min with a linear gradient of 0.1% formic acid in MilliQ water (solution A) and 0.1%
formic acid in ACN (solution B) with the following conditions: isocratically 1% B for 1 min,
followed by 1–12% B for 1 min, 12–40% B for 15 min, 40–85% B for 2 min. For CID-MS/MS,
the electrospray ionization source was operated in positive ion mode and both singly- and
multiply-charged ions were selected for CID-MS/MS at sample cone voltage of 28 V and
source temperature of 100˚C. The LC–MS eluate was continuously scanned from 300 to 1990
m/z in 1 sec and peptide ion MS/MS analysis was performed over the range m/z 50–2000 with
scan time of 0.6 sec. Fragmentation spectra were i) match against the last update of the NCBI
non-redundant database (release 239.0 of 8/18/2020) using the on-line form of the MASCOT
Server (version 2.6) at http://www.matrixscience.com, and ii) processed in Waters Corpora-
tion’s ProteinLynx Global SERVER 2013 version 2.5.2. (with Expression version 2.0). The fol-
lowing search parameters were used: Taxonomy: all entries; enzyme: trypsin (2 missed
cleavage allowed); MS/MS mass tolerance was set to ± 0.6 Da; carbamidomethyl cysteine and
oxidation of methionine were selected as fixed and variable modifications, respectively. The
relative abundances (% of total protein bands area) of antivenom components were estimated
by densitometry of Coomassie-stained SDS-polyacrylamide gels using Image Studio Lite, ver-
sion 5.2 (LI-COR Biosciences) software, and the relative abundances of different proteins con-
tained in the same SDS-PAGE bands were estimated based on the relative ion intensities of the
most abundant MS/MS-derived tryptic peptide ions associated with each protein.
Third-generation antivenomics
Third-generation antivenomics was applied to assess the immunorecognition ability of the
antivenom [43,44]. Antivenoms (INS-COL, PROBIOL, ICP, INS-PERU, UCV, BIOL) were
dialyzed against distilled water, lyophilized, and reconstituted in coupling buffer (0.2 M
NaHCO3, 0.5 M NaCl, pH 8.3). Affinity columns were prepared in batch as follow: 3 mL of
CNBr-activated Sepharose 4B matrix (Ge Healthcare, Buckinghamshire, UK) packed in an
ABT column (Agarose Bead Technologies, Torrejón de Ardoz, Madrid), later washed with
10x matrix volumes of cold 1 mM HCl (to preserve the activity of reactive groups) followed by
two matrix volumes of coupling buffer to adjust the pH of the column to 7.0–8.0. ~100 mg of
each lyophilized antivenom was dissolved in 2x matrix volumes of coupling buffer and incu-
bated with 3 mL CNBr-activated matrix overnight at 4˚C. The amount of coupled protein
(IgG or F(ab’)2) was determined as the difference between the quantity of protein incubated
and the quantity uncoupled measured spectrophotometrically at 280 nm before and after incu-
bation with the matrix. After the coupling, any remaining active-matrix groups were blocked
with 6 mL of 0.1 M Tris-HCl, pH 8.5 overnight at 4˚C and the excess of uncoupled antibody
was eliminated by alternatively washing 6 times with 3x matrix volumes of 0.1 M acetate buffer
(0.5 M NaCl, pH 4.0–5.0), and 3x matrix volumes of 0.1 M Tris-HCl buffer (0.5 M NaCl,
pH 8.5). Five affinity columns each containing 8 mg of immobilized antivenom were equili-
brated with three volumes of PBS (20 mM phosphate buffer, 135 mM NaCl, pH 7.4) and incu-
bated with increasing amounts (100–1200 μg of total venom proteins) of venom (B. asper
(sensu stricto), B. rhombeatus, or B. ayerbei) dissolved in 350 μL of PBS, and the mixtures were
incubated for 1 h at room temperature in an orbital shaker. In parallel, as specificity controls,
the highest amount of venom was incubated with 350 μL of mock matrix and 350 μL of matrix
coupled with 8 mg of naïve equine IgG. The non-retained fractions of columns incubated with
100–300 μg, 600 μg, 900 μg, and 1200 μg were recovered with 2x, 4x, 6x and 8x matrix volumes
of PBS, respectively, and the immunocaptured proteins were eluted with 3x (100–300 μg) and
6x (600–1200 μg) matrix volumes of 0.1M glycine-HCl, pH 2.7 buffer and brought to neutral
pH with 1M Tris-HCl, pH 9.0. The column fractions (non-retained and retained) with highest
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volume (600–1200 μg) were divided equally to avoid concentrating or diluting the total pro-
teins too much as follows: fractions recovered in 600 μg, 1=2; non-retained and retained frac-









aliquots were concentrated in a Savant SpeedVac vacuum centrifuge (ThermoFisher Scientific,
Waltham, MA USA) to 40 μL and fractionated by reverse-phase HPLC using an Agilent LC
1260 High-Pressure Gradient System (Santa Clara, CA, USA) equipped with a Discovery BIO
Wide Pore C18 (15 cm×2.1 mm, 3 μm particle size, 300 Å pore size) column and a DAD detec-
tor. Elution was monitored at 215 nm with a reference wavelength of 400 nm [43,44].
The percentage of immunorecognition was obtained by the integration of RP-HPLC pro-
files of retained and non-retained fractions. The fraction of non-immunocaptured molecules
was estimated as the relative ratio of the chromatographic areas of the proteins recovered in
the non-retained (NR) and retained (R) affinity chromatography fractions applying the equa-
tion %NRi = 100-[(Ri|(Ri+NRi)) x 100], where Ri corresponds to the area of the same protein
“i” in the chromatogram of the fraction retained and eluted from the affinity column. This
result was corrected for toxins such as SVMP which elute with difficulty from the column due
to their high binding affinity to the immobilized antivenom. In this case, the percentage of
non-immunocaptured toxin “i” (% NRtoxin“i”) was calculated as the ratio between the chro-
matographic areas of the same peak recovered in the non-retained fraction (NRtoxin“i”) and
in a reference venom (Vtoxin“i”) containing the same amount of total protein that the parent
venom sample and run under identical chromatographic and experimental conditions, using
the equation %NRtoxin "i" = (NRtoxin "i"/Vtoxin "i") x 100 [45].
Neutralization of biological effects of venoms
The neutralizing capacity of antivenoms manufactured in Colombia (INS-COL, PROBIOL)
and Costa Rica (ICP) towards major bothropic biological effects (i.e., lethality, hemorrhagic,
coagulant, myotoxic, defibrinogenating, edematogenic, indirect hemolytic, and proteolytic),
determined in this study or previously reported by Mora-Obando et al. [28] and Rengifo-Rı́os
et al. [29] for the same venoms, was tested using standardized protocols recommended by the
WHO [46–48] with slight modifications. In particular, although WHO recommends "using
groups of 5–6 mice (of the same strain and weight range used for the LD50 assay) for ED50
determinations, although 10 mice may be needed for some venoms". In our experience with
bothropoid venoms 4 mice groups and 4–6 levels of antivenom:venom ratios provide strong
statistics for calculating ED50s with narrow 95% confidence intervals. Thus, to comply with the
principles of the 3Rs (Replacement, Reduction and Refinement) and the ARRIVE guidelines
(Animal Research: Reporting of in vivo Experiments) (NC3Rs, https://www.nc3rs.org.uk/
arriveguidelines), without compromising the robustness of the ED50 data, here the number of
animals was 4 per antivenom:venom level. The median lethal dose (LD50) of Bothrops rhom-
beatus venom was determined using Probits [28,49]. All neutralization assays were performed
by incubating for 30 min at 37˚C constant amounts of venom (challenge dose) (Table 2) with
increasing dilutions of antivenoms, previously dialyzed and lyophilized and dissolved to a final
concentration of 70 mg/mL in PBS [50]. In each experiment, positive and negative control
mice groups were injected, respectively, with venom in PBS and antivenom alone. After each
assay, mice were euthanized by CO2 inhalation [48].
Neutralization of venom lethality. Groups of four CD-1 mice (16–18 g) received intra-
peritoneal injections of four LD50s (challenge dose) (Table 2) mixed with antivenom in differ-
ent proportions (250–1000 μL antivenom/mg venom) dissolved in PBS. Forty-eight hours
later, the number of surviving mice in each group was recorded. The antivenoms’ capacity to
neutralize the venoms’ lethal activity was expressed as median effective dose (ED50), which
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corresponds to the amount of antivenom that protects 50% of the injected mice [35]. ED50
value and its 95% confidence limits for each venom was calculated using Probit analyses with
software BioStat v. 2008.
Calculation of the venom toxin-specific and venom neutralizing antibody content of
antivenoms. The data from the antivenomics and ED50 experiments were combined to cal-
culate the fraction of anti-toxin and venom neutralizing IgG or F(ab’)2 molecules [41]. Briefly,
the percentage of anti-toxin IgG or F(ab’)2 molecules in the antivenoms was calculated by
dividing [(1/2 maximal amount (in μmoles) of total venom proteins bound per antivenom
vial) x molecular mass (in kDa) of antibody (IgG, 160 kDa or F(ab’)2, 110 kDa) molecule] by
the [total amount of antibody (IgG or F(ab’)2) (in mg) per antivenom vial] [44,51,52]. To cal-
culate the percentage of lethality neutralizing antibodies, the potency (P) of the antivenoms
was first obtained, i.e. the amount of venom (mg) neutralized per 1 mL of each antivenom,
was calculated as P = [(n-1)/ ED50]×LD50, where “n” is the number of LD50s used as challenge
dose to determine the ED50 and, "n-1" is used because at the endpoint of the neutralization
assay, the remaining activity of one LD50 remains unneutralized causing the death of 50% of
mice [53,54]. For the calculation of P, LD50 and ED50 values were expressed, respectively, in
mg venom/mouse and mL of antivenom that protect 50% of the mice population inoculated
with n×LD50. Finally, the antivenom’s potency (P) was divided by the maximal amount of total
venom proteins bound by mL of antivenom [41].
Neutralization of hemorrhagic activity. Groups of four mice (18–20 g) received intra-
dermal injections of 0.1 mL each containing 10 Minimum Hemorrhagic Doses (MHDs) of
venom (Table 2) incubated with increasing dilutions of antivenom (62.5–1000 μL antivenom/
mg venom). Two hours post-injection mice were sacrificed by CO2 inhalation, their skin
removed, and the area of the hemorrhagic lesion photographed. The images were processed
with software Inkscape v. 0.92 as described by Jenkins et al. [55]. The antivenom neutralization
capacity (MHDED50) was defined as the venom/antivenom ratio that reduced the diameter of
the hemorrhagic lesion to 50% compared to the diameter of the lesion in the positive control
[50].
Neutralization of coagulant activity. 0.1 mL aliquots each containing a fixed-dose of
venom (Table 2) incubated with antivenom at different ratios (7.8–1000 μL antivenom/mg
venom) were added to 0.2 mL of citrated human plasma preincubated for 30 min at 37˚C.
Clotting times were recorded and the Effective Dose (ED) of the antivenom was calculated as
the venom/antivenom ratio which prolonged the clotting time three times compared to that of
plasma incubated with venom alone [56].
Neutralization of defibrinogenating activity. Groups of four CD-1 mice (18–20 g)
received intravenous injections of 200 μL of PBS containing two Minimum Defibrinogenating
doses (MDDs) (Table 2) incubated with antivenom at different ratios (62.5–2000 μL
Table 2. Reference doses of B. asper venoms considered for the experimental design of this study.
Lineage LD50 [μg/mouse] MHD [μg] MCD [μg] MDD [μg]
B. asper (sensu stricto) 100.9 (83.2–122.8)a 1.44 ± 0.20a 0.37 ± 0.05a 2.0a
B. rhombeatus 54.9 (36.0–83.8)b 3.55 ± 0.30c 0.21 ±0.03c 3.0b
B. ayerbei 50.1 (37.4–58.3)a 0.24 ± 0.04a 0.96 ± 0.10a 3.0a
LD50: Median Lethal Dose; MHD: Minimum Hemorrhagic Dose; MCD: Minimum Coagulant Dose; MDD: Minimum Defibrinogenating Dose. The challenge doses
were: (a) lethal activity: four LD50; (b) hemorrhagic activity: ten MHD; (c) coagulant activity: two MCD and (d) defibrinating activity: two MDD.
a Mora-Obando et al. [28]
b this work
c Rengifo-Rı́os et al. [29].
https://doi.org/10.1371/journal.pntd.0009073.t002
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antivenom/mg venom). One hour post-injection the animals were anesthetized and bled to
obtain around 0.2 mL of blood, which was left undisturbed for two hours at room temperature.
Neutralization ability of the antivenom was expressed as effective dose (ED), defined as the
lowest venom/antivenom ratio in which blood coagulation occurred in all the mice [56].
Neutralization of myotoxic activity. A fixed-dose of venom (50 μg) incubated with anti-
venom at ratios of 250, 500, and 1000 μL antivenom/mg venom were injected in groups of
four mice (18–20 g) into the right gastrocnemius muscle. 3 h later, a blood sample was
obtained from the caudal vein and the plasma creatine kinase (CK) activity, expressed as units/
L, was measured using a UV kinetic assay (CK-Nac, Biocon Diagnostik). The neutralization
capacity of the antivenom was expressed as ED50, defined as the venom/antivenom ratio where
CK levels were reduced by 50% compared to the positive control [48,57].
Neutralization of edematogenic activity. Each animal of groups of four mice (18–20 g)
received a subcutaneous injection in the right footpad, containing a mixture of 5 μg of venom
incubated with antivenoms at final ratios of 250–1000 μL antivenom/mg venom, in a total vol-
ume of 50 μL of PBS. The left footpad injected with PBS alone served as negative control. Foot-
pads’ thickness, measured using a low-pressure spring caliper (Oditest) 0.5, 1, 3, and 6 h post-
injection, was considered a quantitative indicator of edema, and the data were expressed as
percentage. The antivenoms’ neutralizing capacities were determined at 60 min and the ED50
expressed as the venom/antivenom ratio in which edema was reduced by 50% compared to the
positive control [58].
Neutralization of indirect hemolytic activity. The indirect hemolytic activity of each
venom was determined following the method described by Arce-Bejarano et al. [59], with
slight modifications, using rabbit erythrocytes in a tube fluid phase system. Briefly, rabbit
blood was collected by venipuncture in Falcon tubes containing Alsever’s solution (2.05% dex-
trose, 0.8% sodium citrate, 0.055% citric acid, and 0.42% sodium chloride) as anticoagulant,
and centrifuged at 400 xg for 5 min. Red blood cells were washed five times in 0.14 M NaCl,
0.01 M Tris, pH 7.7 (TBS). 50 μL of a reaction mixture containing a 5% suspension of erythro-
cytes in TBS gently mixed with 0.25% w/v sn-3-phosphatidylcholine was incubated with
250 μL containing various amounts of venom diluted in TBS-Ca2+ (TBS supplemented with
10mMCaCl2, pH 7.7) in 96-well plates. Identical mixtures without venom or replacing venom
by 0.1% Triton X-100 in water were included as negative (0% hemolysis) and positive (100%
hemolysis) controls, respectively. The plates were incubated for 60 min at 37˚C with mild stir-
ring every 20 min, centrifuged at 400 xg for 5 min, and the absorbance of the supernatants
measured at 540 nm using a microwell plate reader was considered a quantitative index of
hemolysis. Experiments were performed in triplicates and the results were expressed as per-
centages of the hemolysis recorded for the positive control. For assessing an antivenom’s neu-
tralization activity, a fixed challenge dose defined as three times the amount of venom that
hemolyzed 50% of the erythrocytes was incubated at increasing ratios of antivenom (250–
1000 μL antivenom /mg venom) for 30 min at 37˚C, after which 50 μL of the 5% suspension of
erythrocytes/0.25% w/v sn-3-phosphatidylcholine was added, and the indirect hemolytic activ-
ity measured as above. The neutralizing capacity of antivenom (ED50) was defined as the
venom/antivenom ratio in which the venom-induced hemolytic activity was reduced by 50%
compared to the positive control [59].
Neutralization of proteolytic activity. The proteolytic activity of each venom was deter-
mined according to the method described by Gutiérrez et al. [50]. Briefly, 20 μL aliquots con-
taining 2.5–40 μg of venom were added to 100 μL of substrate (10 mg/mL azocasein in 25 mM
Tris, 150 mM NaCl, 5 mM CaCl2, pH 7.4) and incubated at 37˚C for 90 min in 96-well plates.
Reactions were stopped by adding 200 μL of 5% trichloroacetic acid and centrifuged (350 xg x
5 min). Hundred fifty μL of supernatant were mixed with the same volume of 0.5 M NaOH
PLOS NEGLECTED TROPICAL DISEASES Testing Latin American antivenoms against SW Colombian B. asper lineage venoms
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0009073 February 1, 2021 11 / 36
and the absorbance at 450 nm recorded. For antivenom neutralization testing, the challenge
dose corresponded to the amount of venom capable of inducing a change in absorbance of 0.5
at 450 nm. Challenge doses of each venom, either alone or incubated with antivenom at several
ratios of (250, 500, and 1000 μL antivenom/mg venom) in a total volume of 25 μL, were tested
as above. The ED50 antivenom’s neutralizing capacity was expressed as the venom/antivenom
ratio in which proteolysis was reduced by 50% compared to the positive control [50].
Enzyme-linked immunosorbent assay (ELISA). Antibody titers of the antivenoms were
determined by ELISA. For this end, 1 μg samples of venom dissolved in 100 μL of PBS (20 mM
phosphate, 135 mM NaCl, pH 7.4), were coated overnight at 4˚C per well of 96-well plates
(Dynatech Immulon, Alexandria, VA). Thereafter, the plates were decanted and free sites in
each venom-coated well was blocked with 100 μl/well of 1% bovine serum albumin (BSA) in
PBS for 30 min at room temperature. Antivenoms dissolved in PBS to a concentration of 70
mg/mL were serially diluted (1:1000–1:128000) in PBS containing 1% BSA, added to the wells
and incubated for 1 h at room temperature. The plates were then washed five times with PBS
and bound antibodies detected following incubation for 1 h at room temperature with 100 μL
of a 1:2000 dilution of anti-horse IgG-phosphatase-conjugate (Sigma, St. Louis, MO, USA) in
FALC buffer (0.05 M Tris, 0.15 M NaCl, 20 μM ZnCl2, 1mM MgCl2, pH 7.4) containing 1%
BSA. Finally, the plates were washed five times with FALC buffer, the substrate p-nitrophenyl
phosphate (1mg/ml) in diethanolamine buffer (1mM MgCl2, 90mM diethanolamine, pH 9.8)
was added, and the absorbance at 405 nm was recorded for 5–60 min using a microplate reader
(Multiskan Labsystems Ltd., Helsinki, Finland).
Statistical analyses
Results were represented as dose-response graphs and reported as the mean ± SD of duplicate,
triplicate, or quadruplicate determinations depending on the biological activity assessed. Anti-
venom ED50s against venom lethality was calculated using the software BioStat v. 2008, and
the values were considered significantly different among groups when the 95% confidence lim-
its did not overlap. ED50s towards venom hemorrhagic, coagulant, edematogenic, proteolytic
and myotoxic activities were calculated from the equations of the regression analyses in Excel
(Microsoft Office 2019). The significance of the differences between the experimental groups
was determined by parametric or non-parametric analysis of variance (ANOVA or Kruskal–
Wallis, respectively), followed by post hoc tests to identify significant differences between
group pairs. Differences with p� 0.05 were considered statistically significant. All the statisti-
cal analyses were performed using Software IBM SPSS Statistics version 23.
Results and discussion
The ability of different mono- and polyvalent experimental and commercial bothropic anti-
venoms to neutralize the most relevant toxic effects produced by B. asper bites was demon-
strated in the late 1990s [60–62], and the outcome clearly showed that the antivenoms were
more effective in preventing the systemic than the local (myotoxic, dermonecrotic and hemor-
rhagic) tissue damaging effects [63–65]. Current antivenoms manufactured in Colombia are
generated from plasma of horses hyperimmunized with mixtures of B. atrox, B. asper and C.d.
cumanensis venoms supplemented (Laboratorios Probiol) or not (Instituto Nacional de Salud,
INS-COL) with venom of the bushmaster L. muta. Given the wide range of B. asper and the
occurrence of intraspecific phylogeographic structure [23,24,32], it is not surprising [62] that
different antivenom effectiveness has been observed regarding the number of vials needed in
the treatment of envenomings inflicted by snakes from Pacific region than from the Andean
region (S. Ayerbe, personal communication). Therefore, the aim of this study was to determine
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the immunological characteristics of a panel of bothropic antivenoms that includes the
national products as well as those imported or potentially importable antivenoms, which may
complement national production in the treatment of envenomings caused by the three lineages
of the B. asper complex distributed in SW Colombia, B. asper (sensu stricto), B. rhombeatus,
and B. ayerbei, whose structural and functional venomics profiles have recently been reported
[28,32].
Physicochemical characterization of the antivenoms
Table 1 summarizes the physicochemical characteristics of the 6 antivenoms (INS-COL, PRO-
BIOL, INS-PERU, ICP, UCV, BIOL) examined. Total protein concentration was similar
among INS-COL, INS-PERU, ICP and BIOL antivenoms, ranging from 56.8 to 59.7 mg/mL,
whereas UCV had lowest (41.9 mg/mL) and PROBIOL presented a much higher (200.7 mg/
mL) protein content. SDS-PAGE analysis (Fig 2) confirmed the type of antibody molecule
specified in the products’ inserts (IgG or F(ab’)2) (Table 1), but also revealed a number of
other protein bands. Protein spots excised from the SDS-PAGE gels were identified through
tandem-mass spectrometry (MS/MS) analysis as aggregation and degradation products of IgG
(Fig 2, yellow-filled circles) and non-IgG proteins (Fig 2, red-filled circles) (S1 Table)
The INS-COL antivenom showed a predominance (82.3%) of intact IgG glycoforms (Fig 2,
bands 2 and 3) and their aggregation (band 1, 2.9%) and degradation (4, 11.6%; 5, 1.3%; 6,
0.7%) products, and a 1.1% of α1B-glycoprotein (Fig 2, band 7). In comparison, PROBIOL
antivenom contained significantly lower intact IgG bands (41.8%), comparable IgG degrada-
tion 137 kDa product (7.1%), and much higher non-IgG contaminants, notably albumin
found in band 16 (Fig 2), accounting for 30.8% of the total antivenom proteins, and other
plasma proteins in bands 8 (α2-macroglobulin, 7.9%), 12 and 13 (haptoglobin, 3.7%), 14 (sero-
transferrin, 4.1%), and 15 (α1B-glycoprotein, 3.7%) (Fig 2 and S1 Table).
Costa Rican ICP and Peruvian INS-PERU antivenoms displayed a very similar SDS-PAGE
banding patterns and MS/MS-derived protein profiles, characterized by 80% intact IgGs,
3–4% IgG aggregates, 12–15% IgG degradation products, and minor non-IgG contaminants
(0.9% vs 1.5% α1B-glycoprotein in bands 22 and 29, respectively; and 2.5% haptoglobin in
band 27 of ICP antivenom) (Fig 2).
Fig 2. SDS-PAGE analysis of the polyvalent antivenoms used manufactured by Instituto Nacional de Salud
(Colombia) (INS-COL), Laboratorios Probiol S.A, (Colombia) (PROBIOL), Instituto Nacional de Salud de Perú
(INS-PERU), Instituto Clodomiro Picado (Costa Rica) (ICP), Centro de Biotecnologı́a de la Unidad de Farmacia
de la Universidad Central de Venezuela, (UCV), and Instituto Biológico Argentino S.A.I.C. (BIOL). Lanes 1a/b or
2a/b, vials used in the experiments. Molecular weight markers (MW) are indicated on the left. Coomassie Brilliant
blue-stained bands labeled 1–37 were excised and submitted to tandem mass spectrometry analysis (S1 Table). Bands
containing IgG aggregation or degradation products are identified by yellow-filled circles. Red-filled circles denote
non-IgG proteins bands.
https://doi.org/10.1371/journal.pntd.0009073.g002
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The F(ab’)2 antivenoms manufactured in Venezuela (UCV) and Argentina (BIOL) exhibit
similar qualitative SDS-PAGE profiles (Fig 2), though the latter represents a better purified
product (88% F(ab’)2, 7.3% IgG degradation product, and 4.4% non-IgG (fibrinogen γ-chain)
contaminant) than the fabotherapic produced by the Universidad Central de Venezuela (70%
F(ab’)2, 9.9% non- processed IgG, 0.5% IgG aggregates, 13.3% IgG degradation products, and
6% α2-macroglobulin) (S1 Table).
The presence of IgG aggregates and non-IgG protein impurities contribute to the reduced
safety profile of the products by increasing the possibility of early (anaphylactoid) reactions
and anaphylactic shock due to IgE antibodies against these heterologous animal proteins
[62,66–69]. The outcome of our present study indicates a need for improving the fractionation
of the hyperimmune plasma, particularly the PROBIOL and UCV products.
Immunoreactivity profile of antivenoms: third-generation antivenomics
The immunoreactivity of the six antivenoms against the venom components of B. asper (sensu
stricto), B. ayerbei, and B. rhombeatus, previously identified by Mora-Obando et al. [28,32] was
investigated by third-generation antivenomics [43–45] (Figs 3–5 and S1–S3). Table 3 summa-
rizes the antivenoms’ immunorecognition capabilities. All the antivenoms recognized around
12–14% of the low-molecular mass components eluted during the first 10 min in chro-
matographic fractions 1–3. These fractions comprise endogenous tripeptide inhibitors of
snake venom metalloproteinases (SVMPi) [70–73], 10–12 amino acid residue bradykinin-
potentiating-like peptides (BPPs) [72,74,75], and disintegrin (DIS) molecules. Among these
early-eluting venom components only disintegrin are immunogenic [76–79], and therefore,
the immunoretained fraction may comprise this class of toxins, which in B. ayerbei [28], B.
asper, and B. rhombeatus [32] represent 2.3–5.6% of their total venom proteins. On the other
hand, chromatographic fractions 4–7, eluted between 10–30 min, comprised disintegrin-like/
cysteine-rich (DC) fragments of PIII-SVMPs, phospholipase A2 (PLA2) molecules, cysteine-
rich secretory proteins (CRISP) and serine proteinases (SVSP), and were immunocaptured at
maximal immunoaffinity column binding capacity with average efficacy of 62% (B. asper),
Fig 3. Immunocapture capacity of polyvalent antivenoms towards B. asper (sensu stricto) venom from Cauca,
Colombia. Panel A displays the fractionation by reverse-phase HPLC of the venom components. Proteins eluting in
each peak (1–14) were assigned using the venomics information reported by Mora-Obando et al. [32]. SVMP, snake
venom Zn2+-metalloproteinase and their proteolytic fragments Disintegrin/Cysteine fragments (DC-frag); PLA2-K49/
D49, phospholipase types Lys49 and Asp49; SVSP, serine proteinase; CTL, C-type lectin-like; DIS, disintegrin; CRISP,
cysteine-rich secretory protein; LAO, L-amino acid oxidase; PDE, phosphodiesterase; SVMPi, SVMP inhibitors; BPP,
bradykinin-potentiating-like peptides. Panels B-G represent RP-HPLC fractionations of the non-immunoretained
fractions recovered in the flow-through fraction of the affinity columns of immobilized antivenoms INS-COL (B),
PROBIOL (C), ICP (D), INS-PERU (E), UCV (F), BIOL (G) incubated with increasing amounts of venom (100–
1200 μg). Panels H and I display to chromatographic separations of the venom fraction not retained in the mock
matrix control and the naïve equine immunoglobulins control, respectively. The numbers on top of the
chromatographic peaks represent the percentage of each fraction.
https://doi.org/10.1371/journal.pntd.0009073.g003
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70% (B. rhombeatus), and 80% (B. ayerbei) (Table 3). Chromatographic fractions 8–14 eluted
between 30–45 min contained SVMP, C-type lectin-like proteins (CTL), SVSP, L-amino acid
oxidase (LAO), and phosphodiesterase (PDE), and were immunoretained in the affinity matri-
ces with average efficacy of 80% (B. asper), 87% (B. rhombeatus), and 69% (B. ayerbei)
(Table 3). Table 4 shows a summary of the maximum total toxin binding capacity of each of
the B. asper linage venoms by the different antivenoms. Extrapolated to mg venom immuno-
captured per gram of antivenom the ranking of antivenoms according to their respective high-
est to lowest binding capacity towards total components was [BIOL> INS-PERU > UCV >
INS-COL > ICP> PROBIOL] for B. asper (sensu stricto), [BIOL > INS-COL > (UCV ~
INS-PERU) > ICP> PROBIOL] for B. rhombeatus, and [INS-COL > (BIOL ~ INS-PERU) >
UCV > ICP> PROBIOL] for B. ayerbei. In terms of percentage of toxin-binding antibodies,
the order from highest to lowest relative abundance was [INS-PERU > (BIOL ~ INS-COL) >
Fig 5. Immunocapture capacity of polyvalent antivenoms towards B. ayerbei venom from Patia river valley, Colombia
(A). Panel A displays the fractionation by reverse-phase HPLC of the venom components. Proteins eluting in each
peak (1–14) were assigned using the venomics information reported by Mora-Obando et al. [28]. Panels B-G represent
RP-HPLC fractionations of the non-immunoretained fractions recovered from the affinity columns of immobilized
antivenoms INS-COL (B), PROBIOL (C), ICP (D), INS-PERU (E), UCV (F), BIOL (G) incubated with increasing
amounts of venom (100–1200 μg). Panels H and I display to chromatographic separations of the venom fraction not
retained in the mock matrix control and the naïve equine immunoglobulins control, respectively. The numbers on top
of the chromatographic peaks represent the percentage of each fraction.
https://doi.org/10.1371/journal.pntd.0009073.g005
Fig 4. Immunocapture capacity of polyvalent antivenoms towards B. rhombeatus venom from Cauca river valley,
Colombia. Panel A displays the fractionation by reverse-phase HPLC of the venom components. Proteins eluting in
each peak (1–14) were assigned using the venomics information reported by Mora-Obando et al. [32]. Panels B-G
represent RP-HPLC fractionations of the non-immunoretained fractions recovered from the affinity columns of
immobilized antivenoms INS-COL (B), PROBIOL (C), ICP (D), INS-PERU (E), UCV (F), BIOL (G) incubated with
increasing amounts of venom (100–1200 μg). Panels H and I display to chromatographic separations of the venom
fraction not retained in the mock matrix control and the naïve equine immunoglobulins control, respectively. The
numbers on top of the chromatographic peaks represent the percentage of each fraction.
https://doi.org/10.1371/journal.pntd.0009073.g004
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UCV > ICP> PROBIOL] for B. asper (sensu stricto), [INS-COL > (BIOL ~ INS-PERU) >
(ICP ~ UCV ~ PROBIOL)] for B. rhombeatus, and [(INS-COL ~ INS-PERU) > BIOL > ( ICP
~ UCV ~ PROBIOL)] for B. ayerbei.
Table 4. Summary of third generation antivenomics analyses of polyvalent antivenoms against venoms of the three B. asper lineages from south-western Colombia.
Antivenom
(antibody type)
mg/vial Venom Maximal binding
capacity













INS-COL (IgG) 568 BAS 47.9 27.2 32.0 12.0 24.0 13.2 54.9
BRH 66.2 37.6 28.0 18.9 37.8 16.9 44.6
BAY 59.2 33.6 40.1 11.8 23.6 12.0 50.7
PROBIOL (IgG) 2007.4 BAS 20.0 40.1 33.8 4.7 9.5 2.5 26.7
BRH 33.1 66.5 25.1 10.6 21.1 3.8 17.8
BAY 25.3 50.8 36.0 5.6 11.2 4.1 36.0
ICP (IgG) 596.7 BAS 32.4 19.4 28.4 9.1 18.2 10.2 56.2
BRH 41.2 24.6 27.9 11.8 23.6 12.0 50.7
BAY 33.8 20.2 43.4 6.2 12.5 9.3 74.3
INS-PERU (IgG) 591.2 BAS 65.2 38.5 31.8 16.4 32.8 N.D N.D
BRH 53.5 31.6 30.8 13.9 27.8 N.D N.D
BAY 54.2 32.0 38.9 11.2 22.3 N.D N.D
BIOL F(ab’)2 592.6 BAS 71.3 42.3 31.4 12.5 25.1 N.D N.D
BRH 75.4 44.7 29.4 14.1 28.2 N.D N.D
BAY 54.4 32.3 42.0 7.1 14.3 N.D N.D
UCV F(ab’)2 419
� BAS 60.8 25.5 29.8 11.2 22.3 N.D N.D
BRH 57.8 24.2 28.1 11.3 22.6 N.D N.D
BAY 42.8 18.0 41.9 5.6 11.3 N.D N.D
BAS: B. asper (sensu stricto), BRH, B. rhombeatus; BAY, B. ayerbei; V, venom; AV, antivenom; Ag, antigen; Abs, antibodies
� Dr. Mariana Cepeda (personal communication, 2020).
�� % Lethality neutralizing Abs per vial/ % of total toxin-binding Abs per vial
https://doi.org/10.1371/journal.pntd.0009073.t004
Table 3. Percentages of NOT immunoretained fractions of B. asper venoms by six Latin American antivenoms.
Venom Fractions� Major venom components % not immunoretained
INS-COL PROBIOL ICP BIOL UCV INS-PERU AVERAGE
B. asper (sensu stricto) 1–3 SVMPi, BPP, DIS 86 92 88 86 85 88 88
4–7 DC-frag, PLA2, CRISP 40 51 50 23 30 31 38
8–14 SVSP, SVMP, CTL, LAO, PDE 15 45 28 9 10 13 20
B. rhombeatus 1–3 SVMPi, BPP, DIS 84 88 88 85 84 87 86
4–7 DC-frag, PLA2, CRISP 23 44 40 18 21 33 30
8–14 SVSP, SVMP, CTL, LAO, PDE 8 28 17 5 11 13 13
B. ayerbei 1–3 SVMPi, BPP, DIS 87 93 91 86 83 91 88
4–7 DC-frag, CRISP, SVSP 12 43 31 11 18 6 20
8–14 SVSP, SVMP, CTL, LAO, PDE 21 54 38 25 27 24 31
The immunocapture efficiency of each antivenom is color-coded based on the percentage of the NOT immunoretained toxin fractions. Dark green: <25%, light green:
25–55%, light brown: 55–80% and red:> 80%. Polyvalent antivenoms manufactured by Instituto Nacional de Salud, Colombia (INS-COL); Laboratorios Probiol S.A.,
Colombia (PROBIOL); Instituto Clodomiro Picado, Costa Rica (ICP); Instituto Biológico Argentino S.A.I.C (BIOL); Centro de Biotecnologı́a de la Unidad de Farmacia
de la Universidad Central de Venezuela (UCV) and Instituto Nacional de Salud, Peru (INS-PERU). � Fraction numbers and abbreviations of the main venom
components are described in Fig 3.
https://doi.org/10.1371/journal.pntd.0009073.t003
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Although none of the antivenom affinity matrices outshined all the others in its ability
to immunocapture each and every one of the components of the three B. asper lineage ven-
oms, the results displayed in S2–S19 Tables and summarized in Tables 3 and 4 clearly clas-
sify the antivenoms into two groups according to their antivenomics immunocapturing
features, with [BIOL, INS-PERU, INS-COL and UCV] (61.3 ± 9.9 (BAS), 63.2 ± 9.7 (BRH),
and 52.7 ± 6.9 (BAY) mgV/gAV) in the top group and [ICP > PROBIOL] (26.2 ± 8.8
(BAS), 37.2 ± 5.7 (BRH), and 29.5 ± 6.0 (BAY) mgV/gAV) in the least effective group. The
same trend was observed when the immunoreactivity of INS-COL, ICP, and PROBIOL
against the three B. asper lineage venoms was comparatively assessed by ELISA: INS-COL
showed the highest titer against all the venoms and the lower levels of cross-reactivity of
ICP and PROBIOL against the three venoms were similar and indistinguishable between
themselves (Fig 6). In addition, comparison of the relative amounts (%) of anti-toxin anti-
bodies in the different antivenoms (Table 4), calculated assuming one antigen binding site
occupied per immobilized antibody molecule, revealed that, on average, 28.5 ± 8.1%,
27.6 ± 5.2%, and 22.5 ± 7.3% of INS-COL, INS-PERU, and BIOL antivenom antibodies,
respectively, recognized antigenic determinants on toxins from each of the three B. asper
lineage venoms, whereas these figures were 18.7 ± 6.5%, 18.1 ± 5.6% and 13.9 ± 6.3% in the
case of UCV, ICP and PROBIOL antivenoms, respectively. INS-COL, PROBIOL and ICP
showed higher percentages of anti-BRH than anti-BAS and anti-BAY antibodies, whereas
BIOL and UCV contained equivalent relative amounts of anti-BAS and anti-BRH, but sig-
nificantly lower % of anti-BAY antibodies, and the relative amounts of anti-toxin antibod-
ies in INS-PERU were BAS > BRH > BAY (Table 4). These figures fall within the range of
percentages (6–28%) of anti-toxin antibodies determined for other commercial antiven-
oms [48,51,52,79–81]. The distinct cross-reactive profiles of the different bothropic anti-
venoms may be ascribed to the immunization process, in particular to the use of venoms
Fig 6. Titration curves of polyvalent antivenoms against the venoms of three lineages of B. asper venoms.
Antivenoms INS-COL (●), PROBIOL (●), ICP (�) were serially diluted by a factor of two (starting from a dilution of 1/
1000) and tested by ELISA against the following crude venoms: B. asper (sensu stricto) (A), B. rhombeatus (B) and B.
ayerbei (C). Equine normal serum was included as negative control (◆). Each point represents the mean ± SD of three
independent determinations. Statistically significant differences were observed among the titers of the antivenoms
INS-COL vs. PROBIOL and/or ICP against the venoms of B. asper (dilutions 1: 1000, 8000, 16000, 64000), B.
rhombeatus (dilutions 1:2000–128000) and B. ayerbei (dilutions 1:1000–16000).
https://doi.org/10.1371/journal.pntd.0009073.g006
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from different Bothrops species or from different geographic variations of the same nomi-
nal species used by the different manufacturers, i.e. INS-COL and PROBIOL (B. atrox, B.
asper), INS-PERU (B. atrox, B. pictus, B. barnetti, B. brazili [82]), ICP (Costa Rican B. asper
from Caribbean and Pacific populations), UCV (B. atrox, B. colombiensis, B. venezuelensis),
BIOL (B. asper of undisclosed geographic origin) [63].
Table 5. Neutralization of biological activities of B. asper venoms by polyvalent antivenoms INS-COL, PROBIOL and ICP.
Venom Activity Challenge dose1
[μgV]
ED50/ED
2 of activities neutralized by polyvalent antivenoms
INS-COL PROBIOL ICP





Lethality 403.6 5.0 (3.4–7.5) 71.4 (48.6–
107.1)
1.0 (0.6–1.6) 14.3 (8.6–
22.9)
3.4 (2.6–4.3) 48.6 (37.1–
61.4)
Potency 3.75 53.6 0.75 10.7 2.55 36.4
Hemorrhage 14.4 13.4 ± 1.2a,b 191.4 ± 17.1 3.2 ± 0.30c 45.7 ± 4.3 6.7 ± 0.64 95.7 ± 9.1
Coagulation 0.74 10.4 ± 0.06a 148.6 ± 0.9 1.6 ± 0.001c 22.9 ± 0.01 7.8 ± 0.05 111.4 ± 0.7
Defibrinogenation 4 4.0 57.1 1.0 14.3 2.0 28.6
Myotoxicity 50 5.5 ± 1.5a 78.6 ± 21.4 2.1 ± 0.2c 30 ± 2.9 3.3 ± 0.6 47.1 ± 8.6
Edematogenic 5 2.15 ± 0.28 30.7 ± 4.0 N.N N.N 1.30 ± 0.25 18.6 ± 3.6
Proteolytic 12.5 3.48 ± 0.07a 49.7 ± 1 1.26 ± 0.1 18 ± 1.4 2.05 ± 0.4 29.3 ± 5.7
Hemolytic 5.1 1.68 ± 0.09 24 ± 1.3 N.N N.N 1.72 ± 0.03 24.6 ± 0.4
B. rhombeatus Lethality 219.6 5.6 (5.0–6.3) 80 (71.4–90) 1.1 (0.6–2.0) 15.7 (8.6–
28.6)
3.9 (2.6–5.8) 55.7 (37.1–
82.9)
Potency 4.20 60.00 0.83 11.8 2.93 41.8
Hemorrhage 35.5 8.2 ± 0.85a 117.1 ± 12.1 3.1 ± 0.62c 44.3 ± 8.9 9.5 ± 0.64 135.7 ± 9.1
Coagulation 0.42 9.7 ± 0.18a 138.6 ± 2.6 1.4 ± 0.001c 20 ± 0.01 9.3 ± 0.06 132.9 ± 0.9
Defibrinogenation 6 2.0 28.6 1.0 14.3 2.0 28.6
Myotoxicity 50 8.9 ± 1.6a 127.1 ± 22.9 2.1 ± 0.7c 30 ± 10 7.7± 3.7 110 ± 52.9
Edematogenic 5 1.48 ± 0.14 21 ± 2.0 N.N N.N 1.00 ± 0.18 14.3 ± 2.6
Proteolytic 12.5 3.00 ± 0.04a 42.9 ± 0.6 0.88 ± 0.03 12.6 ± 0.4 1.55 ± 0.03 22.1 ± 0.4
Hemolytic 5.1 1.65 ± 0.03 23.6 ± 0.4 N.N N.N 1.66 ± 0.03 23.7 ± 0.4
B. ayerbei Lethality 200.4 5.7 (4.9–6.6) 81.4 (70–94.3) 1.7 (0.7–2.4) 24.3 (10–34.3) 4.7 (4.4–5.0) 67.1 (62.9–
71.4)
Potency 4.28 61.1 1.28 18.2 3.53 50.4
Hemorrhage 2.4 7.2 ± 0.68a,b 102.9 ± 9.7 2.7 ± 0.39 38.6 ± 5.6 4.6 ± 1.12 65.7 ± 16
Coagulation 1.92 8.4 ± 0.06a 120.0 ± 0.9 1.5 ± 0.001c 21.4 ± 0.01 6.4 ± 0.01 91.4 ± 0.1
Defibrinogenation 6 1.0 14.3 0.5 7.1 1.0 14.3
Myotoxicity 50 4.4 ± 1.3a 62.9 ± 18.6 1.6 ± 0.9c 22.9 ± 12.9 4.8 ± 0.9 68.6 ± 12.9
Edematogenic 5 1.49 ± 0.67 21.3 ± 9.6 N.N N.N 1.98 ± 0.54 28.7 ± 7.7
Proteolytic 12.5 2.4 ± 0.44a 34.3 ± 6.3 0.99 ± 0.06 14.1 ± 0.9 1.33 ± 0.02 19 ± 0.3
Hemolytic 5.1 N.D N.D N.D N.D N.D N.D
For comparative purposes, neutralization activities were carried out with previously dialyzed and lyophilized antivenoms for antivenomics experiments prepared at a
stock concentration of 70 mg/mL. Polyvalent antivenoms manufactured by Instituto Nacional de Salud, Colombia (INS-COL); Laboratorios Probiol, Colombia
(PROBIOL); Instituto Clodomiro Picado, Costa Rica (ICP). 1Table 2 describes the reference doses and the number of doses used to calculate the challenge dose.
2Neutralization of lethal, hemorrhagic, myotoxic, edematogenic, proteolytic and hemolytic activities is expressed as median effective dose (ED50) and neutralization of
coagulant and defibrinogenating activities is expressed as Effective Dose (ED). Potency was calculated as [(n-1)/ ED50]×LD50 (see Materials and Methods section for
details). Doses in μL antivenom/mg venom were converted to mg venom (V)/mL antivenom (AV) and mg V/g AV. The significant differences among groups, INS-COL
vs. PROBIOL, INS-COL vs. ICP, PROBIOL vs. ICP are represented by letters a, b, and c (superscripts) respectively. N.D: non-determined. N.N: the effect was not
neutralized to 50% even with the highest antivenom/venom ratio.
https://doi.org/10.1371/journal.pntd.0009073.t005
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Neutralization of the biological effects of B. asper venoms by INS-COL,
PROBIOL, and ICP antivenoms
Lethality. As a rule of thumb, immunocapturing capacity� 20–25% of total venom pro-
teins has been proposed to correlate with a promising outcome in an in vivo lethality neutrali-
zation assay [83], and increasing percentages of immunocapturing indicate greater
neutralizing potencies of the corresponding bait antivenoms. Table 5 summarizes the results
of the neutralizing capacities of the Colombian antivenoms INS-COL and PROBIOL and the
Costa Rican ICP towards the lethal, hemorrhagic (Fig 7), coagulant (Fig 8), defibrinogenating,
myotoxic (Fig 9), edematogenic (Fig 10), proteolytic (Fig 11), and indirect hemolytic (Fig 12)
effects of the venoms of SW Colombian B. asper (sensu stricto), B. rhombeatus, and B. ayerbei.
All three antivenoms followed the "antivenomics rule" regarding their potency to neutralize
the lethal effect of the three B. asper lineage venoms, as well as the coagulant and proteolytic
effects (Table 5). Antivenoms INS-COL and ICP showed statistically indistinguishable capaci-
ties to neutralize the indirect hemolytic effect of B. asper and B. rhombeatus venoms, the coag-
ulant effect of B. rhombeatus venom, and the defibrinogenating and myotoxic effects of B.
rhombeatus and B. ayerbei venoms (Table 5).
The fraction of toxin-binding antibody molecules present in the antivenoms INS-COL,
PROBIOL, and ICP, which contributed to protect the test animals from the lethal effect of the
three B. asper lineage venoms, was derived by dividing the percentage of neutralizing antibod-
ies (calculated from the antivenom’s potency, S20 Table) by the percentage of toxin-binding
antibodies (calculated from the maximal total venom protein binding capacity of the
Fig 7. Comparison of the neutralizing capacity of the antivenoms manufactured by INS-COL (A-C), PROBIOL (D-F), ICP (G-I) towards the
hemorrhagic effect caused by the venoms of B. asper (sensu stricto) (●), B. rhombeatus (●), B. ayerbei (�). Hemorrhagic lesions were measured as
hemorrhagic units (HaU) [55] 2 h after intradermal injection of 10 MHD (challenge dose) mixed with antivenom in the ratios indicated in the figure.
Each point represents the mean ± SD of four replicates. In all assays, statistically significant differences (p<0.05) were observed among the ratios 500–
1000 μL antivenom/mg venom compared to the positive control.
https://doi.org/10.1371/journal.pntd.0009073.g007
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antivenom) (B. asper, S2–S4 Tables; B. rhombeatus, S8–S10 Tables; B. ayerbei, S14–S16 Tables).
For these calculations, it was assumed that antibodies immobilized in the affinity columns
bound on average one antigen molecule per IgG/F(ab’)2 molecule, while in solution the same
antibodies would have their two antigen-binding sites occupied. These conditions are based
on the most coherent fitting of the data from a number of combined antivenomics and in vivo
neutralization studies carried out in our laboratory during the last years. The results listed in
Table 4 unveiled that 60.4 ± 12.3%, 50.1 ± 5.2% and 26.8 ± 9.1% of the toxin-binding antibod-
ies of ICP, INS-COL, and PROBIOL contribute to the lethality neutralization activity of these
antivenoms, respectively. Expressed as relative abundance of toxin-neutralizing antibodies per
vial, INS-COL contained the highest value (14.0 ± 2.6%), followed by ICP (10.5 ± 1.4%) and
PROBIOL (3.5 ± 0.9%) (Table 4). The potency (in mg of venom neutralized per gram of anti-
venom antibodies) of INS-COL, ICP and PROBIOL were roughly similar for the three B. asper
lineage venoms (Table 5), with average values of 58.2 ± 4.1, 42.9 ± 7.1, and 13.6 ± 4.1 mg V/g
AV, respectively.
Venoms’ toxic activities. Hemorrhage induced by the three venoms was almost
completely neutralized by INS-COL and ICP antivenoms at a ratio of 1000 μL antivenom/mg
venom (Fig 7A–7C and 7G–7I). At the same ratio, a hemorrhagic lesion between 50 and 100
mm2 was observed with PROBIOL antivenom (Fig 7D–7F). Except for the B. rhombeatus
venom’s lethal effect, which was neutralized with statistically indistinguishable ED50 by
INS-COL and ICP, the neutralizing efficacy of the antivenoms followed the order
INS-COL > ICP> PROBIOL (Table 5). The antivenoms followed the same trend regarding
their coagulant, defibrinogenating neutralization activities (Table 5). In this sense, INS-COL
and ICP antivenoms extended the coagulation time above 30 min at a ratio of 250 μL
Fig 8. Comparison of the neutralizing capacity of the antivenoms manufactured by INS-COL (A-C), PROBIOL (D-F), ICP (G-I) towards the
coagulant effect caused by the venoms of B. asper (sensu stricto) (●), B. rhombeatus (●), B. ayerbei (�). Clotting time was recorded after mixing and
incubating 2 MCD (challenge dose) with different ratios of antivenom, as indicated in the figure, and adding them to human citrated plasma. Each
point represents the mean ± SD of replicates of two independent experiments.
https://doi.org/10.1371/journal.pntd.0009073.g008
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Fig 9. Comparison of the neutralizing capacity of the antivenoms manufactured by INS-COL (A-D), PROBIOL
(E-H), ICP (I-L) towards the myotoxic effect caused by the venoms of B. asper (sensu stricto) (A, E, I), B. rhombeatus
(B, F, J), B. ayerbei (C, D, G, H, K, L). Muscle damage was measured as plasma creatine kinase activity 3 h after
intramuscular injection of 50 μg of venom mixed with antivenom in the ratios indicated in the figure (●). Antivenom
control (�). PBS control (---). Each point represents the mean ± SD of four replicates. Statistically significant
differences (p<0.05) compared to the venom control are represented by asterisks.
https://doi.org/10.1371/journal.pntd.0009073.g009
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antivenom/mg venom (Fig 8A–8C and 8G–8I), while even at a ratio of 500 μL antivenom/mg
venom PROBIOL did not triple the coagulation time compared to the positive control (Fig
8D–8F). The ED50 of PROBIOL to neutralize the coagulant and the defibrinogenating activity
of the three venoms was 2–4 times less effective than those of INS-COL and ICP (p<0.05)
(Table 5).
The myotoxic effect of the venoms was nearly abrogated by INS-COL and ICP antivenoms
at a ratio of 1000 μL antivenom/mg venom (Fig 9A–9D and 9I–9L). Conversely, PROBIOL
antivenom only showed an average neutralization capacity of about 60% at the highest anti-
venom/venom ratios tested (Fig 9E–9H). Consequently, the ED50s of INS-COL and ICP are
statistically indistinguishable from each other and significantly (p<0.05) higher (more effec-
tive) than that of PROBIOL towards each Colombian B. asper lineage venom tested (Table 5).
Both INS-COL and ICP antivenoms effectively neutralized, albeit the Colombian product
exhibiting slightly higher ED50 compared to the Costa Rican antivenom, the edematogenic
effect of B. asper (sensu stricto), B. rhombeatus, and B. ayerbei venoms (Table 5). However,
even at the highest antivenom/venom ratio tested, PROBIOL was unable to reduce the effect
to 50% (Table 5). Edematogenic activity curves, in which the injected animals were monitored
during 360 min (Fig 10A–10I), showed that both INS-COL and ICP antivenoms reduced, at
the highest ratio of antivenom tested and within the first 30 min, > 50% of the edema pro-
duced by all the venoms (Fig 10A–10C and 10G–10I). On the contrary, PROBIOL was only
capable of partly neutralizing (by 30%) the edema triggered by B. rhombeatus venom (Fig
10D–10F). In general, the neutralizing effect of antivenoms was maintained six hours after
Fig 10. Comparison of the neutralizing capacity of the antivenom manufactured by INS-COL (A-C), PROBIOL (D-F), ICP (G-I) towards the
edematogenic effect caused by the venom of B. asper (sensu stricto) (A, D, G), B. rhombeatus (B, E, H) and B. ayerbei (C, F, I). Edema was
measured as the increase in the thickness of footpad compared to the negative control (PBS) and monitored during 6 h after subcutaneous
injection of 5 μg of venom (●) mixed with antivenom in the ratios: 1000 μL antivenom/mg venom (�), 500 μL antivenom/mg venom (Δ), 250 μL
antivenom/ mg venom (■). Each point represents the mean ± SD of four replicates. Statistically significant differences (p<0.05) compared to the
venom control are represented by asterisks.
https://doi.org/10.1371/journal.pntd.0009073.g010
PLOS NEGLECTED TROPICAL DISEASES Testing Latin American antivenoms against SW Colombian B. asper lineage venoms
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0009073 February 1, 2021 22 / 36
venom injection (Fig 10); besides, INS-COL and ICP antivenoms neutralized the vasculotoxic
effect produced by the venom, contributing in parallel to the neutralization of bleeding.
Interestingly, in some experiments involving PROBIOL antivenom/venom mixtures the
edema increased above the size of the positive control (mice injected with venom alone) (Fig
10D–10F). Previous studies performed with B. asper venom from Costa Rica have also
described this circumstance [84]. Proteolytic release of vasoactive peptides from serum protein
contaminants (i.e., α2-globulins) during the incubation time of the antivenom/venom mixture,
affecting vascular permeability and edema formation, has been invoked to explain this phe-
nomenon. The fact that this event was mainly observed in experiments involving the anti-
venom with the most impurities of plasma proteins, PROBIOL (Fig 1 and S1 Table), would
support this explanation.
Proteolytic activity of the three venoms was similar (Fig 11A). This effect is attributed
mainly to the action of serine proteinases and Zn2+-dependent SVMPs present in B. asper
venom [50]. INS-COL antivenom effectively neutralized the proteolytic activity of the three
Colombian B. asper lineage venoms (ED50 = 42.3 ± 7.7 mg venom/g antivenom), followed in
order of potency by ICP and PROBIOL (23.5 ± 5.3, and 14.9 ± 2.8 mg venom/g antivenom),
respectively (Fig 11B and 11C and Table 5).
Indirect hemolytic activity was recorded in B. asper (sensu stricto) and B. rhombeatus ven-
oms, but not in B. ayerbei venom (Fig 12A), as has been previously noted [28]. This effect is
associated to high abundance of myotoxic PLA2s [85] and was quantified measuring the
venom’s phospholipase activity on phosphatidylcholine using erythrocyte lysis as an indicator
[86]. The equivalent indirect hemolytic activity of B. asper (sensu stricto) and B. rhombeatus
(Fig 12B) venoms was neutralized by INS-COL and ICP antivenoms with similar ED50 of
24.0 ± 0.5 mg venom/g antivenom (Table 5), while PROBIOL did not show neutralization effi-
cacy of the indirect hemolytic activity of B. asper (sensu stricto) and B. rhombeatus venoms
even at a ratio of 2000 μL antivenom/mg venom.
Fig 11. Proteolytic activity of the venoms of B. asper (sensu stricto), B. rhombeatus, and B. ayerbei (A) and neutralizing
capacity of the antivenoms manufactured by INS-COL (●), PROBIOL (�) and ICP (●) towards B. asper (B), B.
rhombeatus (C) and B. ayerbei (D). Neutralization of the proteolytic activity was measured on azocasein, as described
in the Material and methods section, 90 min after mixing and incubating 12.5 μg of venom (challenge dose) with
antivenom in the ratios indicated in the figure. Each point represents the mean ± SD of three replicates. Statistically
significant differences (p<0.05) compared to the venom controls are represented by asterisks.
https://doi.org/10.1371/journal.pntd.0009073.g011
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Concluding remarks
Our data confirm and expand previous studies. Otero et al. (2002) reported a comparative
study of the neutralizing capacity of four polyvalent antivenoms manufactured in Colombia
(INS-COL, PROBIOL), Venezuela (UCV), and México (Antivipmyn, Instituto Bioclon)
against the pharmacological and enzymatic effects of the venoms of B. asper and Porthidium
nasutum from Antioquia (northwest Colombia) and Chocó (west Colombia) [38]. In their
study, INS-COL and Antivipmyn antivenoms showed the highest neutralizing efficacy against
the lethal and other pharmacological (hemorrhagic, edema-forming, myonecrotic, defibrino-
genating and indirect hemolytic) effects of B. asper venom pooled from 40–45 specimens from
different regions of Antioquia and Chocó. Conversely, antivenom PROBIOL presented the
lowest neutralizing capacity towards the same activities, and the Venezuelan UCV antivenom
had intermediate neutralization abilities. Understanding the basis of the effectivity of antiven-
oms against homologous and heterologous venoms demands the quantitative assessment of its
toxin-resolved immunorecognition profile. Here we have applied third-generation antive-
nomics to compare the specific and paraspecific immunoreactivity of six bothropic antiven-
oms against three Colombian B. asper lineage venoms. The antivenomics outcome showed
that all the major toxin families, i.e., SVMP, PLA2, CRISP, SVSP, CTL [32], were immunocap-
tured at maximal immunoaffinity column binding capacity with average efficacy of 62–87%
(Table 3). These results clearly indicate that the paraspecificity exhibited by the six bothropic
antivenoms against the three Colombian B. asper lineage venoms is not biased towards any
particular family of toxins but is well balanced among the different venom protein families.
Therefore, our study provides a solid experimental ground to rationalize the reported immu-
nological profiles of INS-COL, UCV, and PROBIOL [38], and other bothropic antivenoms
Fig 12. Indirect hemolytic effect produced by venoms of B. asper, B. rhombeatus, and B. ayerbei (A) and neutralizing
capacity of the antivenoms INS-COL (●), PROBIOL (�) and ICP (●) towards B. asper (sensu stricto) venom (B) and B.
rhombeatus (C). Neutralization of indirect hemolysis was measured on rabbit erythrocytes, as described in the Material
and methods section, 1 h after mixing and incubating of 5.1 μg of venom (challenge dose) with antivenom in the ratios
indicated in the figure. Each point represents the mean ± SD of three replicates. Statistically significant differences
(p<0.05) compared to the venom control are represented by asterisks.
https://doi.org/10.1371/journal.pntd.0009073.g012
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(INS-PERU, ICP, and BIOL), against B. asper venoms from different geographic Colombian
ecoregions. These results strongly suggest the feasibility of adding these antivenoms to the list
of candidates for the treatment of snakebite accidents caused by the species of the B. asper
complex from SW Colombia, B. asper (sensu stricto), B. rhombeatus and B. ayerbei in the
Departments of Nariño and Cauca.
Queiroz and co-workers [87] have reported in vitro qualitative (Western blot) and
semi-quantitative (ELISA) evidence that Brazilian polyspecific pentabothropic (SAB) or
antibothropic-lachesic F(ab’)2 antivenoms exhibited variable paraspecific immunoreac-
tivity towards nineteen venoms of bothropic snakes, including B. brazili, B. alternatus,
B. atrox, B. bilineatus, B. castelnaudi, B. cotiara, B. erythromelas, B. fonsecai, B. insularis,
B. itapetiningae, B. jararaca, B. jararacussu, B. leucurus, B. marajoensis, B. moojeni, B.
neuwiedi, B. pirajai, B. pradoi, and Bothrocophias hyoprorus. The remarkable para-speci-
ficity exhibited by antivenoms generated against immunization mixtures that included
venoms from phylogenetic distant Bothrops species may be ascribed to large conserva-
tion of immunoreactive epitope on venom toxins across much of the natural history of
Bothrops, a genus that had its roots in South America during the middle Miocene, 14.07
(CI95: 16.37–11.75) Mya [88,89] (Fig 13). Biogeographic studies support B. asper as the
first species complex to split from the B. atrox group in the Pliocene, around 3.02–2.32
Mya [90], and cladogenesis into lineages began soon thereafter, towards the end of the
Pliocene [23]. The realization of the existence of large immunological conservation
across Bothrops phylogeny emerged also from studies of the paraspecific effectiveness of
the pentabothropic polyvalent antivenom SAB (soro antibotrópico pentavalente) pro-
duced by Instituto Butantan (São Paulo, Brazil) [52,76,79,91–94] using a pool of venoms
from B. jararaca (50%), B. jararacussu (12.5%), B. moojeni (12.5%), B. alternatus
(12.5%) and B. neuwiedi (12.5%) [95,96]. Further, an assessment of the ability of seven
polyspecific antivenoms, produced in Argentina, Brazil, Perú, Bolivia, Colombia and
Costa Rica using different immunization mixtures, to neutralize lethal, hemorrhagic,
coagulant, defibrinogenating and myotoxic activities of the venoms of B. diporus
(Argentina), B. jararaca (Brazil), B. matogrossensis (Bolivia), B. atrox (Perú and Colom-
bia) and B. asper (Costa Rica) also showed a pattern of extensive cross-neutralization of
all the venoms tested, with quantitative differences in the values of the effective doses of
the antivenoms [93,97]. Similar results were obtained in a comparative a preclinical
assessment of the efficacy of two whole IgG antivenoms, prepared in Perú and Costa
Rica, to neutralize the most relevant toxic effects induced by the venoms of Peruvian
Bothrops atrox, B. brazili, B. barnetti and B. pictus [98]. Both antivenoms were effective
in the neutralization of these four venoms in a rodent model of envenoming, indicating
an extensive immunological cross-reactivity exists between Bothrops spp. venoms from
Perú and Costa Rica.
All the species complex groups within genus Bothrops include taxa that represent the main
medically important venomous snakes in their range [9,99]. Our present results converge with
previous studies in revealing the capacity of a number of bothropic antivenoms to neutralize,
in preclinical tests, homologous and heterologous Bothrops venoms in Central and South
America, and also highlight quantitative differences in their ED50s. The combination of antive-
nomics and in vivo neutralization assays provides relevant information to delineate the species
spectrum and geographic range of clinical applicability of an antivenom. Now, the challenge is
to conduct an extensive study to define the matrix of preclinical effectiveness of all the bothro-
pic antivenoms against all the venoms of (medically relevant) species within the genus
Bothrops.
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Fig 13. Phylogenetic tree of Bothrops highlighting some species reported by [88], whose venoms have been shown
to exhibit remarkable immunoreactivity towards homologous and heterologous antivenoms produced in different
Latin American countries using immunization mixtures that include different bothropic venoms.
https://doi.org/10.1371/journal.pntd.0009073.g013
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Supporting information
S1 Fig. Antivenomics analysis of polyvalent antivenoms towards the venom of B. asper
(sensu stricto). Panel A displays the fractionation by reverse-phase HPLC of the venom com-
ponents. Proteins eluting in each peak (1–14) were assigned using the venomics information
reported by Mora-Obando et al. [32]. Abbreviations for the venom components as in the leg-
end of Fig 2A. Panels B-G represent RP-HPLC fractionations of the immunoretained fractions
recovered in the affinity columns of immobilized antivenoms INS-COL (B), PROBIOL (C),
ICP (D), INS-PERU (E), UCV (F), BIOL (G) incubated with increasing amounts of venom
(100–1200 μg). Panels H and I display to chromatographic separations of the venom fraction
retained in the mock matrix control and the naïve equine immunoglobulins control, respec-
tively.
(TIF)
S2 Fig. Antivenomics analysis of polyvalent antivenoms towards the venom of B. rhombea-
tus. Panel A displays the fractionation by reverse-phase HPLC of the venom components. Pro-
teins eluting in each peak (1–14) were assigned using the venomics information reported by
Mora-Obando et al. [32]. Abbreviations for the venom components as in the legend of Fig 3A.
Panels B-G represent RP-HPLC fractionations of the immunoretained fractions recovered in
the affinity columns of immobilized antivenoms INS-COL (B), PROBIOL (C), ICP (D),
INS-PERU (E), UCV (F), BIOL (G) incubated with increasing amounts of venom (100–
1200 μg). Panels H and I display to chromatographic separations of the venom fraction
retained in the mock matrix control and the naïve equine immunoglobulins control, respec-
tively.
(TIF)
S3 Fig. Immunocapture capacity of polyvalent antivenoms towards the venom of B. ayer-
bei. Panel A displays the fractionation by reverse-phase HPLC of the venom components. Pro-
teins eluting in each peak (1–14) were assigned using the venomics information reported by
Mora-Obando et al. [28]. Abbreviations for the venom components as in the legend of Fig 4A.
Panels B-G represent RP-HPLC fractionations of the immunoretained fractions recovered in
the affinity columns of immobilized antivenoms INS-COL (B), PROBIOL (C), ICP (D),
INS-PERU (E), UCV (F), BIOL (G) incubated with increasing amounts of venom (100–
1200 μg). Panels H and I display to chromatographic separations of the venom fraction
retained in the mock matrix control and the naïve equine immunoglobulins control, respec-
tively.
(TIF)
S1 Table. MS/MS assignment of protein bands excised from SDS-PAGE analysis of the six
polyvalent antivenoms studied.
(XLSX)
S2 Table. Concentration-dependent immunoretained (RET) B. asper (Cauca) venom pro-
teins by INS-COL antivenom affinity column. Maximal binding for each RP-HPLC fraction
is highlighted in yellow background. Green background, amount (in μg) of toxin family pro-
teins immunoretained in the affinity columns.
(XLSX)
S3 Table. Concentration-dependent immunoretained (RET) B. asper (Cauca) venom pro-
teins by PROBIOL antivenom affinity column. Maximal binding for each RP-HPLC fraction
is highlighted in yellow background. Green background, amount (in μg) of toxin family
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proteins immunoretained in the affinity columns.
(XLSX)
S4 Table. Concentration-dependent immunoretained (RET) B. asper (Cauca) venom pro-
teins by ICP antivenom affinity column. Maximal binding for each RP-HPLC fraction is
highlighted in yellow background. Green background, amount (in μg) of toxin family proteins
immunoretained in the affinity columns.
(XLSX)
S5 Table. Concentration-dependent immunoretained (RET) B. asper (Cauca) venom pro-
teins by INS-PERU antivenom affinity column. Maximal binding for each RP-HPLC frac-
tion is highlighted in yellow background. Green background, amount (in μg) of toxin family
proteins immunoretained in the affinity columns.
(XLSX)
S6 Table. Concentration-dependent immunoretained (RET) B. asper (Cauca) venom pro-
teins by UCV antivenom affinity column. Maximal binding for each RP-HPLC fraction is
highlighted in yellow background. Green background, amount (in μg) of toxin family proteins
immunoretained in the affinity columns.
(XLSX)
S7 Table. Concentration-dependent immunoretained (RET) B. asper (Cauca) venom pro-
teins by BIOL antivenom affinity column. Maximal binding for each RP-HPLC fraction is
highlighted in yellow background. Green background, amount (in μg) of toxin family proteins
immunoretained in the affinity columns.
(XLSX)
S8 Table. Concentration-dependent immunoretained (RET) B. rhombeatus (Cauca)
venom proteins by INS-COL antivenom affinity column. Maximal binding for each
RP-HPLC fraction is highlighted in yellow background. Green background, amount (in μg) of
toxin family proteins immunoretained in the affinity columns.
(XLSX)
S9 Table. Concentration-dependent immunoretained (RET) B. rhombeatus (Cauca)
venom proteins by PROBIOL antivenom affinity column. Maximal binding for each
RP-HPLC fraction is highlighted in yellow background. Green background, amount (in μg) of
toxin family proteins immunoretained in the affinity columns.
(XLSX)
S10 Table. Concentration-dependent immunoretained (RET) B. rhombeatus (Cauca)
venom proteins by ICP antivenom affinity column. Maximal binding for each RP-HPLC
fraction is highlighted in yellow background. Green background, amount (in μg) of toxin fam-
ily proteins immunoretained in the affinity columns.
(XLSX)
S11 Table. Concentration-dependent immunoretained (RET) B. rhombeatus (Cauca)
venom proteins by INS-PERU antivenom affinity column. Maximal binding for each
RP-HPLC fraction is highlighted in yellow background. Green background, amount (in μg) of
toxin family proteins immunoretained in the affinity columns.
(XLSX)
S12 Table. Concentration-dependent immunoretained (RET) B. rhombeatus (Cauca)
venom proteins by UCV antivenom affinity column. Maximal binding for each RP-HPLC
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fraction is highlighted in yellow background. Green background, amount (in μg) of toxin fam-
ily proteins immunoretained in the affinity columns.
(XLSX)
S13 Table. Concentration-dependent immunoretained (RET) B. rhombeatus (Cauca)
venom proteins by BIOL antivenom affinity column. Maximal binding for each RP-HPLC
fraction is highlighted in yellow background. Green background, amount (in μg) of toxin fam-
ily proteins immunoretained in the affinity columns.
(XLSX)
S14 Table. Concentration-dependent immunoretained (RET) B. ayerbei (Cauca) venom
proteins by INS-COL antivenom affinity column. Maximal binding for each RP-HPLC frac-
tion is highlighted in yellow background. Green background, amount (in μg) of toxin family
proteins immunoretained in the affinity columns.
(XLSX)
S15 Table. Concentration-dependent immunoretained (RET) B. ayerbei (Cauca) venom
proteins by PROBIOL antivenom affinity column. Maximal binding for each RP-HPLC
fraction is highlighted in yellow background. Green background, amount (in μg) of toxin fam-
ily proteins immunoretained in the affinity columns.
(XLSX)
S16 Table. Concentration-dependent immunoretained (RET) B. ayerbei (Cauca) venom
proteins by ICP antivenom affinity column. Maximal binding for each RP-HPLC fraction is
highlighted in yellow background. Green background, amount (in μg) of toxin family proteins
immunoretained in the affinity columns.
(XLSX)
S17 Table. Concentration-dependent immunoretained (RET) B. ayerbei (Cauca) venom
proteins by INS-PERU antivenom affinity column. Maximal binding for each RP-HPLC
fraction is highlighted in yellow background. Green background, amount (in μg) of toxin fam-
ily proteins immunoretained in the affinity columns.
(XLSX)
S18 Table. Concentration-dependent immunoretained (RET) B. ayerbei (Cauca) venom
proteins by UCV antivenom affinity column. Maximal binding for each RP-HPLC fraction
is highlighted in yellow background. Green background, amount (in μg) of toxin family pro-
teins immunoretained in the affinity columns.
(XLSX)
S19 Table. Concentration-dependent immunoretained (RET) B. ayerbei (Cauca) venom
proteins by BIOL antivenom affinity column. Maximal binding for each RP-HPLC fraction
is highlighted in yellow background. Green background, amount (in μg) of toxin family pro-
teins immunoretained in the affinity columns.
(XLSX)
S20 Table. Neutralization of biological activities of south-western Colombian B. asper line-
age venoms by polyvalent antivenoms (values adjusted according to protein concentration
per vial).
(XLSX)
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quia y Chocó. Aspectos clı́nicos y epidemiológicos (marzo de 1989-febrero de 1990). Acta Médica
Colomb. 1992; 17: 229–249. Available from: http://www.actamedicacolombiana.com/anexo/articulos/
04-1992-04-.pdf.
9. Warrell DA. Snakebites in Central and South America: epidemiology, clinical features, and clinical man-
agement. In: Campbell JA, Lamar WW, editors. The Venomous Reptiles of the Western Hemisphere.
Ithaca, NY: Comstock Publishing Associates, Cornell University Press; 2004. pp. 709–761.
10. Ayerbe S. Ofidismo en Colombia. Enfoque, diagnóstico y tratamiento. In: Ordóñez CA, Ferrada R, Bui-
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47. Gutiérrez JM, Rojas G, Lomonte B, Gené JA, Chaves F, Alvarado J, et al. Standardization of assays for
testing the neutralizing ability of antivenoms. Toxicon. 1990; 28: 1127–9; author reply 1129–1132.
https://doi.org/10.1016/0041-0101(90)90110-s PMID: 2264065
48. Gutiérrez JM, Rojas G, Bogarı́n G, Lomonte B. Evaluation of the neutralizing ability of antivenoms for
the treatment of snake bite envenoming in Central America. In: Bon C, Goyffon M, editors. Envenom-
ings and Their Treatments. Fondation Marcel M´erieux, Lyon; 1996. pp. 223–231.
49. Finney DJ. Statistical method in biological assay. London: Charles Griffin and Company Limited; 1971.
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